drugset / Trial / NCT04623086

Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose

NCT04623086

Phase 4 Completed 59 enrolled University of Washington
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study evaluates direct switching vs use of a bridging dose from insulin glargine to insulin degludec in type 1 DM patients. Half of the participants will receive a bridging insulin glargine dose along with the 1st dose of degludec, while other half will receive a placebo and 1st dose of degludec.

Timeline

Start
2020-02-14
Primary completion
2022-09-07
Completion
2023-12-31

Drugs

EvaluationDrugModalityDoseRoute
Subject insulin degludec Protein / enzyme biologic Subcutaneous
Subject insulin glargine Protein / enzyme biologic Subcutaneous